华兰股份董事反对设立AI医药孙公司，主要股东态度审慎

Core Viewpoint - Two directors of Hualan Co., Ltd. (301093), Cui Ke and Yao Mingfang, voted against the proposal to establish an AI pharmaceutical subsidiary during the board meeting on February 9, 2026, citing concerns over feasibility, governance and risk control requirements, and legal constraints [1] Group 1 - The dissenting votes from the directors reflect a cautious attitude from a major shareholder, Huaxia Jiuying Asset Management Co., Ltd., regarding the company's entry into the technology-intensive AI pharmaceutical sector [1] - Huaxia Jiuying's affiliated party, Ruizhong Life Insurance, is a significant institutional investor in Hualan Co., Ltd., holding 16.38% of the shares [1]